Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions

Pathology and Oncology Research

Volumn 22, Issue 1, 2016, Pages 189-196

  Giaginis, Constantinos ^a,b   Alexandrou, Paraskevi ^a   Delladetsima, Ioanna ^a   Karavokyros, Ioannis ^a   Danas, Eugene ^a   Giagini, Athina ^a   Patsouris, Efstratios ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

Clinicopathological parameters; Cyclooxygenase 2; Hu antigen R; Immunohistochemistry; Thyroid malignancy

Indexed keywords

CYCLOOXYGENASE 2; HU ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; ELAV LIKE PROTEIN 1; ELAVL1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; RECURRENCE RISK; SEX DIFFERENCE; THYROID CANCER; THYROID DISEASE; THYROID NODULE; THYROID PAPILLARY CARCINOMA; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, PAPILLARY; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; HYPERPLASIA; METABOLISM; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; THYROID GLAND; THYROID NEOPLASMS; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; ELAV-LIKE PROTEIN 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; THYROID GLAND; THYROID NEOPLASMS;

EID: 84951906967     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-015-9997-5     Document Type: Article

References (50)

1. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H (1996) Cloning and characterization of HuR, a ubiquitously expressed elav-like protein. J Biol Chem 271:8144–8151
2. Ma WJ, Furneaux H (1997) Localization of the human HuR gene to chromosome 19p13.2. Hum Genet 99:32–33
3. Burd CG, Dreyfuss G (1994) Conserved structures and diversity of functions of RNA-binding proteins. Science 265:615–621
4. Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M (2004) Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A 101:2987–2992
5. Fan XC, Steitz JA (1998) HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci U S A 95:15293–11528
6. Abdelmohsen K, Lal A, Kim HH, Gorospe M (2007) Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 6:1288–1292
7. Yiakouvaki A, Dimitriou M, Karakasiliotis I, Eftychi C, Theocharis S, Kontoyiannis DL (2012) Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J Clin Invest 122:48–61
8. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS (2011) Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 12:1082–1093
9. Ghosh N, Chaki R, Mandal V, Mandal SC (2010) COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62:233–244
10. Leenhardt L, Grosclaude P, Cherie-Challine L (2004) Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee. Thyroid 14:1056–1060
11. Ward EM, Jemal A, Chen A (2010) Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation? Future Oncol 6:185–188
12. Hundahl SA, Fleming ID, Fremgen AM, et al. (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648
13. Gharib H, Papini E (2007) Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin N Am 36:707–735
14. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM (2007) Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:260–269
15. Rhee WJ, Ni CW, Zheng Z, Chang K, Jo H, Bao G (2010) HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A 107:6858–6863
16. Zhang J, Modi Y, Yarovinsky T, et al. (2012) Macrophage beta2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis. Am J Pathol 180:1751–1760
17. Lopez de Silanes I, Lal A, Gorospe M (2005) HuR: post-transcriptional paths to malignancy. RNA Biol 2:11–13
18. Kotta-Loizou I, Giaginis C, Theocharis S (2014) Clinical significance of HuR expression in human malignancy. Med Oncol 31:161
19. Giaginis C, Alexandrou P, Tsoukalas N, et al. (2015) Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. Tumour 36:315–327
20. Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M (2008) miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A 105:20297–20302
21. Abdelmohsen K, Kim MM, Srikantan S, et al. (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9:1354–1359
22. Srikantan S, Gorospe M (2012) HuR function in disease. Front Biosci (Landmark Ed) 17:189–205
23. Rosai J (2004) Appendix C. Staging of cancer. In: Houston M (ed) Rosai and Ackerman’s Surgical Pathology, 9th edn. Mosby, London, pp. 2809–2810
24. Tuttle RM, Tala H, Shah J, et al. (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid 20:1341
25. Michailidi C, Giaginis C, Stolakis V, et al. (2010) Evaluation of FAK and Src expression in human benign and malignant thyroid lesions. Pathol Oncol Res 16:497–507
26. Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E, Theocharis S (2014) Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol 35:61–71
27. Karidis NP, Giaginis C, Tsourouflis G, et al. (2011) Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit 17:BR257–BR265
28. Cha JD, Li S, Cha IH (2011) Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma. Head Neck 33:627–637
29. Zhang C, Xue G, Bi J, et al. (2014) Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma. Tumour Biol 35:73–80
30. Wang J, Wang B, Bi J, Zhang C (2011) Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Medical Oncol 28:S577–S585
31. Lim SJ, Kim HJ, Kim JY, Park K, Lee CM (2007) Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 26:229–234
32. Liang PI, Li WM, Wang YH, et al. (2012) HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer 12:611
33. Sun DP, Lin CY, Tian YF, et al. (2013) Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumour Biol 34:3059–3069
34. Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimaki A (2006) Prognostic significance of cyclin a in gastric cancer. Int J Cancer 119:1897–1901
35. Denkert C, Koch I, von Keyserlingk N, et al. (2006) Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 19:1261–1269
36. Zhu Z, Wang B, Bi J, et al. (2013) Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol 34:2299–22308
37. Erkinheimo TL, Lassus H, Sivula A, et al. (2003) Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 63:7591–7594
38. Marechal R, Van Laethem JL (2009) HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment. Expert Rev Anticancer Ther 9:1439–1441
39. Krawczyk-Rusiecka K, Lewiński A (2010) Cyclooxygenase-2 expression and its association with thyroid lesions. Arch Med Sci 6:653–657
40. Casey MB, Zhang S, Jin L, Kajita S, Lloyd RV (2004) Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocr Pathol 15:107–116
41. Lee KJ, Jung YS, Kim WH, Yoon TI, Joo HJ, Soh EY (2008) Cyclooxygenase-2 expression in human thyroid disease. J Endocrinol Investig 31:111–118
42. Lee HM, Baek SK, Kwon SY, et al. (2006) Cyclooxygenase 1 and 2 expressions in the human thyroid gland. Eur Arch Otorhinolaryngol 263:199–204
43. García-González M, Abdulkader I, Boquete AV, Neo XM, Forteza J, Cameselle-Teijeiro J (2005) Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland. Virchows Arch 447:12–17
44. Ito Y, Yoshida H, Nakano K, et al. (2003) Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 42:492–497
45. Siironen P, Ristimäki A, Nordling S, Louhimo J, Haapiainen R, Haglund C (2004) Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 44:490–497
46. Filippova N, Yang X, Wang Y, et al. (2011) The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res 9:648–659
47. Hostetter C, Licata LA, Witkiewicz A, et al. (2008) Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 7:1496–1506
48. Costantino CL, Witkiewicz AK, Kuwano Y, et al. (2009) The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 69:4567–4572
49. Williams TK, Costantino CL, Bildzukewicz NA, et al. (2010) pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One 5:e15455
50. McAllister F, Pineda DM, Jimbo M, et al. (2014) dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. Cancer Biol Ther 15:688–698